Abstract | INTRODUCTION: METHODS: RESULTS: CONCLUSIONS:
|
Authors | Yun-Ju Chen, Ming-Hsin Yeh, Meng-Chieh Yu, Ya-Ling Wei, Wen-Shu Chen, Jhen-Yu Chen, Chih-Yu Shih, Chih-Yen Tu, Chia-Hung Chen, Te-Chun Hsia, Pei-Hsuan Chien, Shu-Hui Liu, Yung-Luen Yu, Wei-Chien Huang |
Journal | Breast cancer research : BCR
(Breast Cancer Res)
Vol. 15
Issue 6
Pg. R108
(Nov 12 2013)
ISSN: 1465-542X [Electronic] England |
PMID | 24216290
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Boronic Acids
- NF-kappa B
- Proteasome Inhibitors
- Pyrazines
- Quinazolines
- Lapatinib
- Bortezomib
- Erlotinib Hydrochloride
- EGFR protein, human
- ERBB2 protein, human
- ErbB Receptors
- Receptor, ErbB-2
- I-kappa B Kinase
- Gefitinib
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Boronic Acids
(administration & dosage, pharmacology)
- Bortezomib
- ErbB Receptors
(antagonists & inhibitors)
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- I-kappa B Kinase
(metabolism)
- Lapatinib
- Mice, SCID
- NF-kappa B
(metabolism)
- Phosphorylation
(drug effects)
- Proteasome Inhibitors
(pharmacology)
- Pyrazines
(administration & dosage, pharmacology)
- Quinazolines
(administration & dosage, pharmacology)
- Receptor, ErbB-2
(antagonists & inhibitors)
- Triple Negative Breast Neoplasms
(drug therapy, metabolism)
- Xenograft Model Antitumor Assays
|